6th CNS Drug Delivery

CNS drug development is facing a new era, thanks to huge strides in neuroscience innovation, including advances in blood-brain barrier transport, CSF administration, and device-mediated delivery, to solve the field's most pressing challenge: access to the brain.

Riding the wave of drug delivery innovation, the industry's definitive 6th CNS Drug Delivery Summit returns to showcase breakthrough progress in receptor-mediated transcytosis, CSF dose escalation, quantifying brain distribution, BBB modeling, CED and FUS technology, emerging modalities including LNPs, and more.

Join 100+ of your industry colleagues from the likes of Roche, Biogen, UCB, JCR, Ionis, Denali, Eli Lilly, Alector, Novartis, Bristol Myers Squibb, Sanofi, and Takeda as they seek to discover and translate safer, more effective brain delivery technologies to change the trajectory of CNS drug development.

URLs:
Website: https://go.evvnt.com/2571802-0?pid=10018
Tickets: https://go.evvnt.com/2571802-2?pid=10018
Brochure: https://go.evvnt.com/2571802-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 3597.00,
Drug Developer Pricing - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + Workshop Day: USD 5197.00,
Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Arash Moshkforoush, Senior Scientist, Denali Therapeutics, Bruno Godinho, Senior Scientist, Atalanta Therapeutics, Chris Kadamus, Executive Director of Engineering, DDCS Eli Lilly, Dallas Bednarczyk, Associate Director, Novartis, Elizabeth Rhea Research Assistant Professor, Division of Gerontology, University of Washington, Eric Distad, Vice President, Clinical Development Cerebral Therapeutics, Harshal Shah, Head of Device Strategy and Innovation Sanofi, Iosif Pediaditakis, Director of Neuroscience, Alchemab Therapeutics, Ismail Hafez Director, Formulation and Delivery Sciences, Ionis Pharmaceuticals, Jingjing Gao, Assistant Professor, Biomedical Engineering, University of Massachusetts, John McGuire, Senior Director, Clinical and Regulatory Affairs, Alcyone Therapeutics, Lisa Shafer, Vice President, Product Development and Reg CMC, Medical Devices and Packaging Biogen, Lu Shan, Senior Director, Antibody Discovery and Protein Engineering Alector, Mathias Schmidt, Chief Executive Officer, JCR Pharmaceuticals, Max Woolley, Head of Drug Delivery Device Research and Product Development, Renishaw, Michelle Boyd, Boyd Neuro Consulting (formerly Cerebral Therapeutics), Nick Todd, Assistant Professor Brigham and Women's Hospital, Niels Janssen, Group Head DMPK/PD Roche, Pawel Stocki, Vice President Research Ossianix, Peter Horanyi, Senior Principal Scientist UCB, Rachael Miller, Research Scientist University of Massachusetts Chan Medical School, Sho Sato, Senior Scientist Takeda, Smrithi Padmakumar, Drug Product Development Senior Scientist Spark Therapeutics, Stergios Zacharoulis Associate Professor of Pediatric Oncology, Senior Director of Pediatric Oncology Columbia University Irving Medical Center, Bristol Myers Squibb, Steve Krausert, Vice President, Supply Chain and Planning Passage Bio, Vijay Agarwal Founder, President, and Chief Executive Officer Alpheus Medical, William Elmquist, Distinguished Professor, Department of Pharmaceutics University of Minnesota, Yuan Yuan, Associate Scientific Director Biogen